✨ Free AI Report
Regeneron Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Regeneron Pharmaceuticals, Inc.
Company Research

Regeneron Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Regeneron Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong blockbuster portfolio driven by Dupixent and EYLEA HD with significant late-stage pipeline expansion and R&D investment positioning the company for sustainable growth despite near-term pricing headwinds. Dupixent full-year 2025 global net sales increased 26% to $17.8 billion, driving strong collaboration revenue. Fourth-quarter 2025 net sales of Eylea HD.

What is Regeneron Pharmaceuticals, Inc.'s industry? Regeneron Pharmaceuticals, Inc. (regeneron.com) operates in Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech. AskCyborg classifies Regeneron Pharmaceuticals, Inc. under Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech in its company registry.

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Full year 2025 revenues increased 1% to $14.3 billion. The company ...

7/ 10Strong

Cyborg Score thesis

Strong blockbuster portfolio driven by Dupixent and EYLEA HD with significant late-stage pipeline expansion and R&D investment...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech
5 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Regeneron Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Regeneron Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Regeneron Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Regeneron Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Regeneron Pharmaceuticals, Inc. Overview

Pro stress-test →

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Full year 2025 revenues increased 1% to $14.3 billion. The company demonstrated strong 2025 commercial performance, particularly within its retina and immunology franchises.

Strategic Profile

Pro stress-test →

Regeneron operates as a unique biopharmaceutical company built on proprietary platforms such as VelocImmune technology and the Regeneron Genetics Center, enabling rapid discovery of therapeutic candidates and efficient delivery of innovative medicines. The company's platform-driven approach delivered 14 internally discovered approvals over the past 15 years, averaging roughly one major approval annually. 2026 is framed as a pivotal year, with multiple regulatory filings, clinical milestones, and new product launches on the horizon.

Competitive Landscape

Pro stress-test →

Regeneron competes in the immuno-oncology and ophthalmology markets against major pharma and biotech companies. In immunology, competitors include Sanofi (Dupixent partner), AstraZeneca, and Novartis in the allergy/asthma space. In ophthalmology, the company faces competitive pressure from other anti-VEGF therapies with its EYLEA HD platform. The company's oncology programs like Libtayo position it against checkpoint inhibitor developers.

Industry Context

Regeneron Pharmaceuticals, Inc. operates in Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech.

Key facts

Founded: 1989 · Headquarters: Tarrytown, US · Employees: N/A · Revenue: $14.3B · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Regeneron Pharmaceuticals, Inc..

  • Dupixent achieved $17.8 billion in 2025 sales with 26% annual growth, solidifying its blockbuster status across immunology franchises.
  • CEO emphasized robust pipeline across multiple therapeutic areas with $6 billion in 2026 R&D investment supplemented by $7 billion in capital expenditures, signaling aggressive innovation agenda.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Collaboration agreement with Tessera Therapeutics for alpha-1 antitrypsin deficiency gene editing therapy became effective
  • January 2026EYLEA HD approved by FDA for macular edema following retinal vein occlusion with monthly dosing flexibility; prefilled syringe decision expected Q2 2026
  • +2 moreTrack every material event for Regeneron Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Regeneron Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupixentLeading immunology blockbuster for eczema, asthma, and atopic dermatitis→EYLEA HDHigh-dose anti-VEGF therapy for retinal diseases with flexible dosing→LibtayoImmunotherapy for cutaneous squamous cell carcinoma and other cancers→ImfinziAnti-PD-L1 checkpoint inhibitor competing in immuno-oncology→AvastinAnti-VEGF therapy competing in ophthalmology market→

Compare Regeneron Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Regeneron Pharmaceuticals, Inc. operates in Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech research →
NEW · MCP server

Ask your AI assistant about Regeneron Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Regeneron Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Regeneron Pharmaceuticals, Inc. do this quarter?”
“Is Regeneron Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Regeneron Pharmaceuticals, Inc. do?+
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Full year 2025 revenues increased 1% to $14.3 billion. The company ...
What is Regeneron Pharmaceuticals, Inc.'s Cyborg Score?+
Regeneron Pharmaceuticals, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Regeneron Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Dupixent, EYLEA HD, Libtayo, Imfinzi. The full competitive landscape is in the AskCyborg report.
How can I get the full Regeneron Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Regeneron Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Regeneron Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals & Therapeutics - Specialty Pharma research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Regeneron Pharmaceuticals, Inc.